Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

MLA

Partanen, Anu, et al. “Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.” Cancers, vol. 16, no. 5, Feb. 2024. EBSCOhost, https://doi.org/10.3390/cancers16051024.

APA

Partanen, A., Waage, A., Peceliunas, V., Schjesvold, F., Anttila, P., Säily, M., Uttervall, K., Putkonen, M., Carlson, K., Haukas, E., Sankelo, M., Szatkowski, D., Hansson, M., Marttila, A., Svensson, R., Axelsson, P., Lauri, B., Mikkola, M., Karlsson, C., … Silvennoinen, R. (2024). Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group. Cancers, 16(5). https://doi.org/10.3390/cancers16051024

Chicago

Partanen, Anu, Anders Waage, Valdas Peceliunas, Fredrik Schjesvold, Pekka Anttila, Marjaana Säily, Katarina Uttervall, et al. 2024. “Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.” Cancers 16 (5). doi:10.3390/cancers16051024.